Reply to : "MetALD accounts for a large part of what we call MASLD!"

Source
Journal of hepatology - ISSN 0168-8278-81:6 (2024) p. e285-e286
Author(s)

Spleen stiffness-based algorithms are superior to Baveno VI criteria to rule out varices needing treatment in patients With advanced chronic liver disease

Source
The American journal of gastroenterology - ISSN 0002-9270-119:8 (2024) p. 1515-1524
Author(s)

Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction

Source
Gastroenterology - ISSN 0016-5085-167:2 (2024) p. 1-20
Author(s)

Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease

Source
Cell death and differentiation - ISSN 1350-9047-31 (2024) p. 1113-1126